Press Releases

Press Releases

Continued growth in 2019 marked by new HD-X product launch, acquisition of the leading neurofilament light (Nf-L) antibody supplier, new corporate headquarters and new ground-breaking neurodegenerative research proving the utility of digital biomarkers ac | July 11, 2019
BILLERICA, Mass.--(BUSINESS WIRE)--
June 26, 2019
Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplier
June 04, 2019
Chairman and CEO Kevin Hrusovsky to present at BIO and provide details about the HD-X launch and vision for continuing to pioneer disruption in healthcare with digital biomarkers
May 29, 2019
World-class facility will offer the Company nearly three times the space for disruptive biomarker technology innovation and to accomm
May 16, 2019
Grants to be awarded to researchers with the most transformative ideas for disrupting precision medicine through biomarker research in Quanterix’ Accelerator Lab  
May 10, 2019
64% Q1 revenue growth and 650 bps gross margin improvement
May 06, 2019
Leading global neurology conference will feature 36 new Simoa-powered studies validating the use of Neurofilament light chain (Nf-L) as a potential diagnostic and prognostic biomarker for neurodegeneration   May 06, 2019 11:30 AM Eastern Daylight Time
March 28, 2019
Amol brings global pharmaceutical and diagnostic industry experience to management team to support rapid company growth and scaling